For example, a plasmid that encodes GP5 is designed to be controlled by a human cytomegalovirus promoter, which can induce anti-GP5-specific neutralizing antibodies and prevent the occurrence of viremia and the development of typical macroscopic lung disease after challenge with the virulent IAF-Klop strain of PRRSV. This evidence concerns the gene GP5 and lung disorder.